Executives and leadership changes across genomic diagnostics and spatial biology signal continued emphasis on commercialization and platform scaling. GeneDx appointed Mark Gardner as president, bringing experience from Quest Diagnostics and prior leadership at OmniSeq, which Labcorp acquired. MyOme said Premal Shah is stepping down as CEO, without a transition effective date or replacement announced in the report. Broken String Biosciences appointed Bruce Eaton as board chairman, while Revolune named Adrian Arechiga as chief commercial officer to expand multiplex immunofluorescence reagent commercialization. Separately, 4basebio added Jeff Coller to its strategic advisory board, strengthening expertise in RNA biology and therapeutics. Together, the moves reflect ongoing board and management adjustments in companies building or deploying genomic tools.